Skip to content
XPR
content.
Press releases
Video
Podcasts
Op-eds
Lists
Guest posts
Author:
Aptevo Therapeutics
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
August 14, 2026
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
August 13, 2026
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
August 12, 2026
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
July 27, 2026
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
June 30, 2026